Mobile App

Google Play Apple Store
Quarterly Brief (July-September, 2022): A Current Expert Analysis on Important HIV Clinical Decisions
AMA/ANCC/ACPE Activities
New frontiers for HIV therapy continue to be explored, as underscored by the clinical development and use of new agents, changing regimen strategies and development of long-acting novel agents. This expanding era of simplified and effective HIV therapy presents physicians with many new opportunities and challenges for providing care. To deliver state-of-the-art HIV prevention and care, healthcare providers must stay informed regularly of new clinical data and treatment recommendations in HIV.

This educational Quarterly Brief, covering HIV data from July through September of 2022 will discuss the most clinically relevant information regarding HIV Cure and Treatment, ART and Pregnancy and Coinfections and Non-ART.
Review the Full Program or segment of interest. Claim up to 0.5 AMA, ANCC, or ACPE credit/contact hour(s) after completion of a brief post-test/evaluation.










Faculty Chair
Paul Sax, MD Paul Sax, MD
Clinical Director
Division of Infectious Diseases
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Faculty
Eric Daar, MD Eric Daar, MD
Chief, Division of HIV Medicine
Harbor - UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA

20

Supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.


Launch Date: October 18, 2022

Release Date: October 18, 2022

Expiration Date: September 30, 2023

September 30, 2023
Mini Module
7471
QuarterlyBrief2022_WebBanner(1150).gif
HIV